{
    "nctId": "NCT04540692",
    "briefTitle": "Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer",
    "officialTitle": "NEOSAMBA Clinical Trial - Stage I",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 444,
    "primaryOutcomeMeasure": "Invasive disease-free survival (IDFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female participants, with at least 18 years old on the day of signing the free and informed consent;\n* Invasive breast carcinoma stage III (RH positive) or IIB/III (RH negative), according to TNM 8th edition; Histologically confirmed diagnosis of invasive breast carcinoma (with any histology), HER-2 negative;\n* The participant (or legally acceptable representative, if applicable) provides written informed consent for the study;\n* The participant must agree to use a contraceptive as detailed in Appendix B of this protocol during the treatment period and for at least 120 days after the last dose of the study treatment;\n* Have a functional capacity according to the Eastern Cooperative Oncology Group (ECOG) from 0 to 2. The evaluation of the ECOG must be carried out within 7 days before the inclusion date.\n* Have adequate organic function. The samples must be collected within 60 days before the start of the study treatment;\n* Have adequate cardiac function as assessed by echocardiogram or MUGA performed up to 60 days before the start of treatment under study.\n\nExclusion Criteria:\n\n- Individuals who do not meet the inclusion criteria above-mentioned.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}